Most importantly, as indicated by experimental studies, future clinical improvement for patients bearing ALK-positive tumors will likely stem from associating an ALK TKI with one of these alternate therapies, bringing synergy to kill tumor cells. The gene discussed is ALK; the disease is neoplasm.